Guan (2020)
Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis
https://doi.org/10.1183/13993003.00547-2020
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098485/
Comorbidities
No. of comorbidities (With 2 or more comorbidities vs. Not present)
COVID-19 (severe/fatal)
Hazard ratio: 2.590 (1.610-4.170) Adjusted model

China

Retrospective case study

Medical records

1590

1590 laboratory-confirmed COVID-19 hospitalized cases from 575 hospitals in 31 province/autonomous regions/provincial municipalities

Mean age was 48.9 years. 686 patients (42.7%) were females. 647 (40.7%) patients were managed inside Hubei province, and 1334 (83.9%) patients had a contact history of Wuhan city. The most common symptom was fever on or after hospitalisation (88.0%), followed by dry cough (70.2%). Fatigue (42.8%) and productive cough (36.0%) were less common. At least one abnormal chest CT manifestation (including ground-glass opacities, pulmonary infiltrates and interstitial disorders) was identified in more than 70% of patients. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached to the composite endpoints during the study.

Median

10 Day


COVID-19 (severe/fatal)

131

Patients who reached composite endpoints, which consisted of admission to intensive care unit, or invasive ventilation or death.


Comorbidities

No. of comorbidities

With 2 or more comorbidities, e.g. diabetes, hypertension and other cardiovascular and cerebrovascular diseases

Not present

With 2 or more comorbidities

130


Hazard ratio

2.590 (1.610-4.170)

No

Yes

Yes

age and smoking status


The HR was 1.79 (95%CI 1.16??2.77) among patients with at least one comorbidity and 2.59 (95%CI 1.61??4.17) among patients with two or more comorbidities.

Average

Yes